Dyadic International, Inc. entered into agreements on August 13, 2026, to raise approximately $2.9 million in gross proceeds through a registered direct offering and concurrent private placement of warrants. The company issued 3,625,000 shares of common stock at $0.795 per share and sold 3,625,000 warrants exercisable at $0.84 per share for $0.005 each. Closing is expected on August 14, 2026, with net proceeds allocated to general corporate purposes, including research and development, working capital, and potential acquisitions. The company operates in the biotechnology industry, developing recombinant protein solutions.

Dyadic International reported second-quarter 2026 financial results for the period ended June 30, 2026. Total revenue was $961,138, a decrease of 0.6% from the prior year period, driven by lower research and development revenue partially offset by increased grant revenue. The company reported a net loss of $2,123,884, or $(0.06) per share, compared to a net loss of $1,793,774 in the same period last year. Loss from operations widened to $2,054,204 due to higher costs of revenue and general and administrative expenses, despite lower research and development spending. Cash and equivalents stood at $1,425,364 as of June 30, 2026. Dyadic International is a global biotechnology company that produces precision-engineered, animal-free proteins and enzymes using proprietary microbial platforms.

Dyadic International, Inc. announced on July 24, 2026, that Nasdaq has confirmed the company's compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), ensuring its common stock will continue to be listed and traded on the Nasdaq Capital Market. Dyadic Applied BioSolutions is a biotechnology company developing recombinant protein production platforms.

Dyadic International, Inc. held its 2026 Annual Meeting of Shareholders on June 18, 2026. Shareholders approved the board of directors' authorization to effect a discretionary reverse stock split within a range specified in the company's Proxy Statement. Additionally, Seth J. Herbst, M.D. was elected as a Class I director to serve until the 2029 Annual Meeting. The meeting also included the ratification of Crowe LLP as the independent registered public accounting firm and an advisory vote on executive compensation. Dyadic International, Inc. is a healthcare company focused on molecular diagnostics.

Dyadic International, Inc. received a notification from Nasdaq on June 18, 2026, initiating delisting proceedings due to failure to comply with the Bid Price Rule, which requires a minimum $1.00 share price. The company failed to regain compliance by the June 17, 2026, deadline and did not meet the $5 million shareholders' equity requirement necessary for an extension. Additionally, the company is in violation of Continued Listing Standards regarding minimum equity, market value, or net income. Dyadic plans to request a hearing before an independent Nasdaq hearings panel to seek an extension through December 15, 2026. Dyadic International, Inc. is a biotechnology company focused on microbial protein production platforms.